uniQure files AMT-130 gene therapy BLA for Huntington's, Ultragenyx apazunersen fails Phase 3 in Angelman, Typewriter emerges from stealth with $56M.
Read digest →Teva anti-IL-15 hits celiac Phase 2a endpoint, Simcere-Roche sign $1.53B tri-specific antibody deal, Inventiva NATiV3 MASH data on track for Q4.
Read digest →Novartis remibrutinib meets Phase 3 endpoints in relapsing MS, GSK mRNA flu advances to Phase 3, Alumis TYK2 lupus miss, RedHill nabs Rebyota rights.
Read digest →Samsung publishes PolyPeptide tender prospectus, Ascendis-BioMarin settle YUVIWEL patent dispute with royalties, BioVie completes Long COVID Phase 2.
Read digest →FDA approves BESREMi ropeginterferon for ET, Arrowhead plozasiran ESC 12-month data, Novo ziltivekimab ZEUS Phase 3 fails, LIBREXIA milvexian miss.
Read digest →FDA clears first-in-class hepcidin peptide rusfertide for polycythemia vera, Cytokinetics wins non-obstructive HCM, Moderna Spikevax gets UK MHRA nod.
Read digest →FDA clears Gilead Bixlenvo for HIV and Priovant Lisraya for dermatomyositis, Moderna raises $2B for cancer vaccine, DualityBio inks Genentech ADC deal.
Read digest →FDA approves Rasonque for pancreatic cancer, Biohaven licenses Kv7 to SK for $795M, BMS ends Cellares alliance, AstraZeneca amylin data at EASD.
Read digest →Eisai-Biogen Leqembi Iqlik weekly SC lecanemab available in US. BioMarin acquires Alesta for $275M oral HPP. J&J Imaavy FDA-approved. Haisco-Sentivera license.
Read digest →Jazz-Zymeworks Ziihera FDA approval for first-line HER2+ GEA. Intismeran forecast >$1B by 2031. Roche HM17321 positioning. Regenxbio RGX-121 clinical hold.
Read digest →Hanmi-Genentech $190M+$2.3B deal for UCN2 obesity peptide HM17321. Gilead Trodelvy+Keytruda EU. Barclays M&A reopens. Capricor deramiocel CRL.
Read digest →Merck-Moderna INTerpath-001 intismeran+Keytruda Phase 3 melanoma hits RFS and DMFS. Capricor deramiocel PDUFA. WuXi Bestchrom sale. BioMarin buys Alesta.
Read digest →Xianweida ecnoglutide EECOH-2 Lancet publication. Chinese peptide pipeline: Gan & Lee, Xianweida, Wayne Biotech. Capricor deramiocel PDUFA. Hengrui HRS-4729.
Read digest →Amylyx $500.2M closes Friday. Vivani NPM-139 semaglutide implant +20% at 1 year. Chinese Minwei-Innovent GLP-1 progress. Regeneron Pasatru FOP.
Read digest →Amylyx upsizes offering to $500.2M at $35.50/share. Mankind-Chenan insulin India deal. Tolerance Bio licenses NT-I7 IL-7 fusion. Network Bio $50M launch.
Read digest →Amylyx AMLX +48.6% weekly to $35.11 on LUCIDITY, $350M raise, Guggenheim $55/Mizuho $30 PT lifts. Silence closes $201.3M. AMX0318 long-acting follow-on.
Read digest →Amylyx avexitide LUCIDITY hit primary endpoint: 55% hypoglycemic reduction, p<0.001. NDA by end 2026. Aizen $100M AI oral peptide deal. LEO buys dersimelagon.
Read digest →Obesity runners-up (Structure, Amgen, Pfizer) chase Lilly-Novo. Aleniglipron 16.3%. Biogen felzartamab China approval. Frontiers AMP cancer review.
Read digest →